Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2010 1
2012 1
2017 3
2018 1
2021 2
2022 6
2023 6
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Molenaar IQ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, Lopez-Yurda M, Swijnenburg RJ, Punt CJA; Dutch Colorectal Cancer Study Group. Bond MJG, et al. Lancet Oncol. 2023 Jul;24(7):757-771. doi: 10.1016/S1470-2045(23)00219-X. Epub 2023 Jun 14. Lancet Oncol. 2023. PMID: 37329889 Clinical Trial.
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.
van der Kleij MBA, Guchelaar NAD, Meertens M, Westerdijk K, Giraud EL, Bleckman RF, Groenland SL, van Eerden RAG, Imholz ALT, Vulink AJE, Otten HM, Fiebrich-Westra HB, Lubberman FJE, Desar IME, Moes DAR, Touw DJ, Koolen SLW, Gelderblom H, Reyners AKL, van Erp NP, Mathijssen RHJ, Huitema ADR; Dutch Pharmacology Oncology Group (DPOG); Steeghs N. van der Kleij MBA, et al. Among authors: vulink aje. Br J Cancer. 2024 Sep;131(5):843-851. doi: 10.1038/s41416-024-02789-2. Epub 2024 Jul 6. Br J Cancer. 2024. PMID: 38971952 Free PMC article.
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
Vliek S, Hilbers FS, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, Lips EH, Mulder L, Kayembe MT, Loo CE, Russell NS, Vrancken Peeters MTFD, Holtkamp MJ, Schot M, Baars JW, Honkoop AH, Vulink AJE, Imholz ALT, Vrijaldenhoven S, van den Berkmortel FWPJ, Meerum Terwogt JM, Schrama JG, Kuijer P, Kroep JR, van der Padt-Pruijsten A, Wesseling J, Sonke GS, Gilhuijs KGA, Jager A, Nederlof P, Linn SC. Vliek S, et al. Among authors: vulink aje. NPJ Breast Cancer. 2023 Sep 9;9(1):75. doi: 10.1038/s41523-023-00580-9. NPJ Breast Cancer. 2023. PMID: 37689749 Free PMC article.
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.
Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, de Vries N, Rosing H, Otten H, Vulink AJE, Desar IME, Imholz ALT, Gelderblom H, van Erp NP, Beijnen JH, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: vulink aje. Ann Oncol. 2022 Oct;33(10):1071-1082. doi: 10.1016/j.annonc.2022.06.010. Epub 2022 Jun 28. Ann Oncol. 2022. PMID: 35777707 Free article.
Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer.
Baltussen JC, Mooijaart SP, Vulink AJE, Houtsma D, Van der Deure WM, Westerman EM, Oosterkamp HM, Spierings LEAMM, van den Bos F, de Glas NA, Portielje JEA. Baltussen JC, et al. Among authors: vulink aje. Breast Cancer Res Treat. 2024 Jul;206(2):337-346. doi: 10.1007/s10549-024-07312-y. Epub 2024 Apr 16. Breast Cancer Res Treat. 2024. PMID: 38627318 Free PMC article.
Mental health outcomes in older breast cancer survivors: Five-year follow-up from the CLIMB study.
Lemij AA, de Glas NA, Derks MGM, Linthorst-Niers EMH, Guicherit OR, van der Pol CC, Lans TE, van Dalen T, Vulink AJE, Merkus JWS, van Gerven L, van den Bos F, Rius Ottenheim N, Liefers GJ, Portielje JEA. Lemij AA, et al. Among authors: vulink aje. Eur J Cancer. 2023 Jul;187:87-95. doi: 10.1016/j.ejca.2023.04.001. Epub 2023 Apr 5. Eur J Cancer. 2023. PMID: 37130464 Free article.
Physical Function and Physical Activity in Older Breast Cancer Survivors: 5-Year Follow-Up from the Climb Every Mountain Study.
Lemij AA, Liefers GJ, Derks MGM, Bastiaannet E, Fiocco M, Lans TE, van der Pol CC, Vulink AJE, van Gerven L, Guicherit OR, Linthorst-Niers EMH, Merkus JWS, van Dalen T, Portielje JEA, de Glas NA. Lemij AA, et al. Among authors: vulink aje. Oncologist. 2023 Jun 2;28(6):e317-e323. doi: 10.1093/oncolo/oyad027. Oncologist. 2023. PMID: 36943287 Free PMC article.
Predicting postoperative complications and their impact on quality of life and functional status in older patients with breast cancer.
Lemij AA, van der Plas-Krijgsman WG, Bastiaannet E, Merkus JWS, van Dalen T, Vulink AJE, van Gerven L, Guicherit OR, Linthorst-Niers EMH, Lans TE, van der Pol CC, Wyld L, Morgan JL, Portielje JEA, de Glas NA, Liefers GJ. Lemij AA, et al. Among authors: vulink aje. Br J Surg. 2022 Jun 14;109(7):595-602. doi: 10.1093/bjs/znac014. Br J Surg. 2022. PMID: 35470383
Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer.
Lemij AA, de Glas NA, Derks MGM, Bastiaannet E, Merkus JWS, Lans TE, van der Pol CC, van Dalen T, Vulink AJE, van Gerven L, Guicherit OR, Linthorst-Niers EMH, van den Bos F, Kroep JR, Liefers GJ, Portielje JEA. Lemij AA, et al. Among authors: vulink aje. Breast Cancer Res Treat. 2022 Jun;193(3):567-577. doi: 10.1007/s10549-022-06583-7. Epub 2022 Apr 19. Breast Cancer Res Treat. 2022. PMID: 35441273 Free PMC article.
Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Molenaar-Kuijsten L, Braal CL, Groenland SL, de Vries N, Rosing H, Beijnen JH, Koolen SLW, Vulink AJE, van Dongen MGJ, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Molenaar-Kuijsten L, et al. Among authors: vulink aje. Clin Pharmacol Ther. 2022 Feb;111(2):477-484. doi: 10.1002/cpt.2455. Epub 2021 Nov 6. Clin Pharmacol Ther. 2022. PMID: 34674222 Clinical Trial.
23 results